Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions
US-2017290782-A1 · Oct 12, 2017 · US
Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatment of tumorous pathologies
US10017442B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10017442-B2 |
| Application number | US-201715849650-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 20, 2017 |
| Priority date | Jun 16, 2015 |
| Publication date | Jul 10, 2018 |
| Grant date | Jul 10, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol or its derivatives/chemical variants in the manufacture of a medicament for the treatment of tumors or cancers. The dihydrostilbenes can be used in the treatment or delay of progression of a cancer in a patient or used in a pharmaceutical formulation for the aforementioned purposes.
First claim
Opening claim text (preview).
What we claim: 1. A method of treating colorectal, melanoma and pancreatic carcinoma by administering to a subject in need thereof an effective dosage of a compound of formula (2) 2. The method according to claim 1 wherein said compound is dihydro-resveratrol. 3. The method according to claim 1 wherein said compound is trans-3,5,4′-trihydroxybibenzyl. 4. The method according to claim 1 wherein said effective dosage ranges from 1.62 mg/kg to 8.13 mg/kg in body weight per day. 5. The method according to claim 1 wherein said effective dosage is 8.13 mg/kg in body weight per day. 6. The method according to claim 4 wherein said subject is human. 7. The method according to claim 5 wherein said subject is human. 8. The method according to claim 1 wherein said compound is administered in situ to site of the colorectal, melanoma and pancreatic carcinoma. 9. The method according to claim 8 wherein said compound is administered intraperitoneally to said subject in need thereof. 10. The method according to claim 1 wherein said subject is human. 11. The method according to claim 1 wherein the compound is administered every other day for an effective period of time. 12. The method according to claim 11 wherein said effective period of time is no less than 21 days.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title
Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations · CPC title
with at least one hydroxy group on a non-condensed ring · CPC title
- A61K8/347Primary
Phenols · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10017442B2 cover?
- The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4′-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol or its derivatives/chemical variants in the manufacture of a medicament for the treatment of tumors or cancers. The dihydrostilbenes can be…
- Who is the assignee on this patent?
- Univ Hong Kong Baptist Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K8/347. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).